Stomach Cancer Treatment Market Size, Share & Trends Analysis Report By Treatment Type, By End Use, By Region, And Segment Forecasts, 2019 To 2025

The global stomach cancer treatment market is expected to witness significant growth over the forecast period. Stomach cancer is a type of cancer that begins when the cancer cells form in the inner lining of the stomach. Stomach cancer is also known as gastric cancer. Gastric cancer usually progresses slowly. Some of the early symptoms include indigestion, heartburn, slight nausea, loss of appetite, etc. But, as the stomach tumor grows there may be more serious symptoms such as stomach pain, vomiting, yellowish eyes or skin, blood in stool, constipation, swelling in stomach, weight loss, etc.

Treatment for gastric cancer basically depends upon the stage of cancer. There are a number of types of treatment available such as surgery, targeted drugs, chemotherapy, etc. The factors that propel the growth of the global market include innovations in treatment, a growing number of cancer treatment centers, increasing research and development activities, and combination therapies.

In addition, the growing prevalence of lymphoma, adenocarcinoma, gastrointestinal stromal tumors, carcinoid tumors, etc. are also driving the growth of the global market. On the other hand, there are also factors that hamper the growth of the market such as high cost of therapy and lack of sufficient financial support from health insurance policies.

In addition, there are also other factors that restrain the growth of the market such as strict monitoring processes for approving the complicated nature of radiation devices and also less availability of commercial drugs for the treatment of stomach cancer. The global stomach cancer treatment market is classified on the basis of treatment type, end use, and geography.

On the basis of treatment type, the global gastric cancer market is classified as surgery, chemotherapy, adjuvant chemotherapy, targeted drugs therapy, and radiation therapy. The targeted drugs therapy segment is further sub-classified as Sunitinib (Sutent), Trastuzumab (Herceptin), and Imatinib (Gleevec).

Among the treatment type, the targeted therapy segment is projected to account for a large share of the global gastric cancer treatment market over the forecast period. The major factor attributed to the growth of targeted therapy is the delivery of advanced techniques such as stem cell therapy, immunotherapy, or enzyme therapy.

On the basis of end user, the global stomach cancer treatment market is divided into hospitals, clinics, specialized cancer treatment centers, and ambulatory surgical centers. Among the end user, hospitals, and specialized cancer treatment centers segments together account a maximum share of the global market. On the basis of geography, the global market is classified as North America, Latin America, Eastern Europe, Western Europe, and Asia Pacific excluding Japan, Japan, and Middle East & Africa.

The North American region comprises the U.S. and Canada. Latin America comprises Mexico and Brazil. The Western European region comprises Germany, Italy, France, England, Spain, Nordic countries, Belgium, The Netherlands, and Luxembourg. The Eastern European region comprises Poland and Russia. Asia Pacific region comprises China, India, ASEAN, and Australia & New Zealand. The Middle East and Africa region comprise GCC, South Africa, and North Africa.

In the case of geographical region, Asia-Pacific followed by Latin America is the most important market for stomach cancer treatment due to the large patient pool in case of stomach cancer. Whereas, gastric cancer treatment market in regions such as North America and Africa are projected to witness slow growth owing to the low occurrence rate of stomach cancer. Some of the prominent players that fuel the growth of the global market include Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck KGaA, Novartis International AG, and Otsuka Holdings Co. Ltd.